Hong Kong Gillian Science Co., Ltd. Beijing Representative Office

The primary objectives of this study are to: Describe the incidence of adverse events in patients with chronic HCV infection treated with sofosbuvir-containing regimens in routine clinical practice Secondary objectives of this study are to: Describe the rate of sustained virologic response approximately 12 weeks after cessation of treatment, defined as the proportion of patients with HCV RNA < LLOQ approximately 12 weeks after cessation of treatment

To evaluate the pharmacokinetics of single and repeated dosing of Sofosbuvir/GS-5816 fixed-dose combination (FDC) tablets in healthy Chinese subjects. To evaluate the safety and tolerability of single and repeated dosing of SOF/GS-5816 FDC tablets in healthy Chinese subjects.

To evaluate the efficacy of 12 weeks of sofosbuvir (SOF)/GS-5816 treatment in subjects with chronic HCV infection, as measured by the proportion of subjects achieving a sustained virologic response 12 weeks after stopping treatment (SVR12); To evaluate the safety and tolerability of 12 weeks of SOF/GS-5816 treatment